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Modified 2010 Classification Criteria
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Objective. The American College of Rheumatology
(ACR) 1990 fibromyalgia classification criteria are
based on the presence of widespread pain and tender-
ness. In 2010, new criteria were proposed that focused
more on multiple symptoms, and these criteria were
later modified to require only self report of symptoms.
The current study aimed to determine the population
prevalence of fibromyalgia and to compare differences
in prevalence using the alternative criteria.
Methods. A cross-sectional survey was conducted.
Questionnaires, including items on pain, symptoms,
and rheumatologic diagnoses, were mailed to 4,600
adults in northeast Scotland. Participants who had
chronic widespread pain or those who met the modified
2010 criteria, plus a subsample of other participants,
were invited to attend a research clinic. Attendees
completed an additional questionnaire and underwent a
rheumatologic examination, and their signs and symp-
toms were classified according to the ACR 1990, 2010,
and modified 2010 criteria. The prevalence of fibromy-
algia according to each set of criteria was calculated,
weighting back to the target population by age, sex, and
area of residence.
Results. Of 1,604 questionnaire participants, 269
were invited to attend the research clinic, and 104 (39%)
attended; 32 of these subjects (31%) met >1 set of
fibromyalgia criteria. The prevalence of fibromyalgia
according to the 1990, 2010, and modified 2010 criteria
was 1.7% (95% confidence interval [95% CI] 0.7–2.8),
1.2% (95% CI 0.3–2.1), and 5.4% (95% CI 4.7–6.1),
respectively. The ratio of females to males was 13.7:1,
4.8:1, and 2.3:1 of those meeting the respective criteria
sets.
Conclusion. Fibromyalgia prevalence varies with
the different sets of classification criteria applied. In
particular, prevalence is higher and a greater propor-
tion of men are identified with the modified 2010 criteria
as compared to the criteria sets requiring clinician
input. This has important implications for the use of the
new criteria, both in research and in clinical practice.
Fibromyalgia is one of the most common reasons
for referring a patient to a rheumatologist (1), and while
there are a number of estimates of the occurrence of
fibromyalgia in rheumatology clinic populations, there
are few studies of its prevalence in the general popula-
tion. Data from a national health interview survey in
Denmark estimated the prevalence to be 1% (2).
Other investigators have reported a prevalence of 2.4%
in Spain (3); and in North America, estimates vary from
2.0% to 3.3% (4,5). Fibromyalgia prevalence increases
with age, reaching a peak around the seventh decade of
life, and at every age it is more common in women than
in men (4).
Supported by the University of Aberdeen Development Trust
from charitable donations for research in the study of fibromyalgia.
1Gareth T. Jones, PhD, Marcus Beasley, MSc, Elisa Flu¨ß,
PhD, Gary J. Macfarlane, MD, PhD: University of Aberdeen, Ab-
erdeen, UK; 2Fabiola Atzeni, MD, PhD: University of Aberdeen,
Aberdeen, UK, and L. Sacco University Hospital, Milan, Italy;
3Piercarlo Sarzi-Puttini, MD: L. Sacco University Hospital, Milan,
Italy.
Address correspondence to Gareth T. Jones, PhD, Epidemi-
ology Group, Institute of Applied Health Sciences, University of
Aberdeen, School of Medicine and Dentistry, Polwarth Building,
Foresterhill, Aberdeen AB25 2ZD, UK. E-mail: gareth.jones@abdn.
ac.uk.
Submitted for publication February 12, 2014; accepted in
revised form October 2, 2014.
568
Table 1. American College of Rheumatology 1990 criteria for the classification of fibromyalgia
1. History of widespread pain
Definition: Pain is considered widespread when all of the following are present: pain in the left side of the body, pain in the right side
of the body, pain above the waist, and pain below the waist. In addition, axial skeletal pain (cervical spine or anterior
chest or thoracic spine or low back) must be present. In this definition, shoulder and buttock pain is considered as pain
for each involved side. “Low back” pain is considered lower segment pain.
2. Pain in 11 of 18 tender point sites on digital palpation
Definition: Pain, on digital palpation, must be present in at least 11 of the following 18 tender point sites:
Occiput: Bilateral, at the suboccipital muscle insertions
Lower cervical: Bilateral, at the anterior aspects of the intertransverse spaces at C5–C7
Trapezius: Bilateral, at the midpoint of the upper border
Supraspinatus: Bilateral, at the origins, above the scapula spine near the medial border
Second rib: Bilateral, at the second costochondral junctions, just lateral to the junctions on the upper surfaces
Lateral epicondyle: Bilateral, 2 cm distal to the epicondyle
Gluteal: Bilateral, in the upper outer quadrants of the buttocks in the anterior fold of the muscle
Greater trochanter: Bilateral, posterior to the trochanteric prominence
Knee: Bilateral, at the medial fat pad proximal to the joint line
Digital palpation should be performed with an approximate force of 4 kg. For a tender point to be considered “positive,” the subject must
state that the palpation was painful.“Tender” is not to be considered “painful.”
* For classification purposes, a patient will be said to have fibromyalgia if both criteria are satisfied. Widespread pain must have been present for
at least 3 months. The presence of a second clinical disorder does not exclude the diagnosis of fibromyalgia. Reformatted from ref. 6.
Table 2. American College of Rheumatology 2010 preliminary diagnostic criteria for fibromyalgia
A patient satisfies the diagnostic criteria for fibromyalgia if the following 3 conditions are met:
1. A Widespread Pain Index (WPI) of 7 and a Symptom Severity (SS) Scale score of 5, or a WPI between 3–6 and an SS scale score of
9
2. Symptoms have been present at a similar level for at least 3 months
3. The patient does not have a disorder that would otherwise explain the pain
Ascertainment
WPI: Note the number of areas in which the patient has had pain over the previous week. In how many areas has the patient had pain?
Score will be between 0 and 19.†
Shoulder girdle (left and right) Jaw (left and right)
Upper arm (left and right) Chest
Lower arm (left and right) Abdomen
Hip (buttock, trochanter) (left and right) Upper back
Upper leg (left and right) Lower back
Lower leg (left and right) Neck
SS: For each of the symptoms of fatigue, waking unrefreshed, and cognitive symptoms, indicate the level of severity over the previous
week, using the following scale:
0  no problem
1  slight or mild problems, generally mild or intermittent
2  moderate, considerable problems, often present and/or at a moderate level
3  severe: pervasive, continuous, life-disturbing problems
Considering somatic symptoms in general, indicate whether the patient has the following:‡
0  no symptoms
1  few symptoms
2  a moderate number of symptoms
3  a great deal of symptoms
The SS scale score is the sum of the severity of the 3 symptoms (fatigue, waking unrefreshed, and cognitive symptoms) plus the
extent (severity) of somatic symptoms in general. The final score is between 0 and 12.
 Reformatted from ref. 7.
† Areas indicated as left and right should be scored separately.
‡ Somatic symptoms that might be considered are as follows: muscle pain, irritable bowel syndrome, fatigue/tiredness, thinking or remembering
problems, muscle weakness, headache, pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, constipation, pain in the
upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud’s phenomenon, hives/welts,
ringing in the ears, vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun
sensitivity, difficulties with hearing, easy bruising, hair loss, frequent urination, painful urination, and bladder spasms.
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All of the above-cited studies used the American
College of Rheumatology (ACR) 1990 criteria for the
classification of fibromyalgia (6), comprising 1) a history
of chronic widespread pain (pain present for at least 3
months and affecting the left and right sides of the body,
above and below the waist, and in the axial skeleton)
plus 2) pain on digital palpation in 11 of 18 specific
sites (Table 1).
In 2010, new classification criteria for fibromyal-
gia were proposed (the “ACR preliminary diagnostic
criteria” [7]), which differed from the 1990 criteria in 2
main respects: first, the 2010 criteria operationalized the
measurement of chronic widespread pain, and second—
and more fundamentally—they did away with the re-
quirement for a tender point examination in favor of an
assessment of fatigue, waking unrefreshed, cognitive
symptoms, and somatic symptoms in general. Under
these new criteria, a patient would be classified as having
fibromyalgia if a clinician determined that they had
1) high levels of pain plus moderate levels of symptoms
or moderate levels of pain plus high levels of symptoms,
2) symptoms present at a similar level for 3 months,
and 3) no disorder that would otherwise explain the pain
(Table 2). These criteria have not been formally adopted
and are only “approved by the ACR Board of Directors
as provisional” (7).
Then, in 2011, a modified version of the 2010
criteria was proposed that relied on self-reported pain
and a simplified self-reported version of somatic symp-
toms (8) for use in clinical and epidemiologic studies.
These preliminary research criteria are referred to here-
inafter as the modified 2010 criteria (Table 3).
The prevalence of fibromyalgia according to the
ACR modified 2010 criteria was assessed in a large
population survey in Germany (9). Fifty-two of 2,445
participants were found to have fibromyalgia, yielding a
prevalence of 2.1%. Given the reliance on self report
and the absence of clinical judgment, one might expect
an elevated estimate of prevalence. However, the au-
thors concluded that the modified 2010 criteria did not
result in high levels of fibromyalgia. It is not known,
however, what the prevalence of fibromyalgia in this
population would have been if the 1990 classification
criteria had been used and, therefore, to what extent this
is a valid conclusion.
To the best of our knowledge, there have been no
published studies of fibromyalgia comparing the ACR
1990, 2010 (preliminary diagnostic), and modified 2010
(preliminary research) classification criteria for fibromy-
algia in the general population. Thus, the aim of the
current study was, first, to determine the prevalence of
fibromyalgia in the general population, second, to com-
Table 3. Modification of the American College of Rheumatology 2010 preliminary diagnostic criteria for fibromyalgia
Criteria
A patient satisfies the modified 2010 fibromyalgia diagnostic criteria if the following 3 conditions are met:
1. A Widespread Pain Index (WPI) of 7 and a Symptom Severity (SS) Scale score of 5, or a WPI between 3–6 and an SS Scale score
of 9
2. Symptoms have been present at a similar level for at least 3 months
3. The patient does not have a disorder that would otherwise sufficiently explain the pain
Ascertainment
WPI: Note the number of areas in which the patient has had pain over the previous week. In how many areas has the patient had pain?
Score will be between 0 and 19.†
Shoulder girdle (left and right) Jaw (left and right)
Upper arm (left and right) Chest
Lower arm (left and right) Abdomen
Hip (buttock, trochanter) (left and right) Upper back
Upper leg (left and right) Lower back
Lower leg (left and right) Neck
SS: For each of the symptoms of fatigue, waking unrefreshed, and cognitive symptoms, indicate the level of severity over the previous
week, using the following scale:
0  no problem
1  slight or mild problems; generally mild or intermittent
2  moderate; considerable problems; often present and/or at a moderate level
3  severe: pervasive, continuous, life-disturbing problems
The SS Scale score is the sum of the severity of the 3 symptoms above plus the sum of the number of the following symptoms
occurring during the previous 6 months: headaches, pain or cramps in the lower abdomen, and depression (0–3). The final score is
between 0 and 12.
 Reformatted, with permission, from ref. 8.
† Areas indicated as left and right should be scored separately.
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pare the prevalence estimates obtained using the estab-
lished (ACR 1990) and the 2 proposed (ACR 2010 and
ACR modified 2010) classification criteria sets, and
third, to determine the main influences of any differ-
ences in identified cases when using the alternative
criteria sets.
SUBJECTS AND METHODS
Study overview. A 2-stage population-based prevalence
study was conducted during the last quarter of 2012 and the
first quarter of 2013. This consisted of a cross-sectional postal
questionnaire survey, followed by a clinical examination of a
subset of survey participants.
Population survey. In the UK, the majority of health-
care is provided by the National Health Service (NHS); it is
estimated that in 2009, only 3% of all general practice consul-
tations were undertaken by private primary care practitioners
(10). Thus, the NHS general practice lists provide a convenient
population-based sampling frame for epidemiologic research.
A sample of 4,600 individuals 25 years of age was randomly
selected from the NHS register in Grampian, northeast Scot-
land, a region with a single city (Aberdeen) and a mixture of
suburban and rural areas, with a mid-year 2010 population
estimate of 340,000 persons 25 years of age.
Selected individuals were sent an advance letter, indi-
cating that they had been chosen for the study. This was
followed 1 week later by the survey pack. The pack consisted of
an invitation letter, an information sheet, the questionnaire,
and a prepaid reply envelope. Two weeks later, a duplicate
pack was sent to nonrespondents. Participants were asked the
following question, “Thinking back over the past four weeks,
have you had any aches or pains that have lasted for one day or
longer?” Those answering “yes” were directed to shade the
location of these pains on 4-view blank body manikin drawings
and were asked whether they had experienced these pains for
3 months. They were also asked whether they had experi-
enced pain or tenderness over the past 7 days in each of the
areas listed in the Widespread Pain Index of the ACR modi-
fied 2010 fibromyalgia criteria, plus they were asked the
questions that comprise the Symptom Severity Scale of the
same criteria set (Table 3). They were also asked to report
whether they had ever been told by a healthcare provider that
they had one or more of the following: osteoarthritis (con-
firmed by radiography), rheumatoid arthritis, osteoporosis,
lupus, scleroderma, ankylosing spondylitis, gout, or fibromyal-
gia.
Clinical examination. Participants who had a positive
result on the screening questionnaire were those who reported
1) chronic widespread pain as per the ACR 1990 criteria
and/or 2) fibromyalgia according to the ACR modified 2010
criteria.
In order to determine what proportion met the various
criteria for fibromyalgia, these individuals were invited to
attend the University of Aberdeen Clinical Research Facility
for further examination. It was also important, however, to
establish whether any participants who screened negative were
deemed to have fibromyalgia on subsequent examination.
Therefore, a subsample of participants who reported 1) pain
that did not meet the above definition or 2) no pain was also
invited to attend.
In the clinic, participants completed a second question-
naire and underwent a clinical examination by a single exam-
iner (FA, a consultant rheumatologist). This included a full
clinical history and tender point examination, as per the ACR
1990 criteria for fibromyalgia.
Prevalence of fibromyalgia. The numbers of fibromy-
algia cases were determined as follows. For the ACR 1990
criteria, data were derived from the clinic questionnaire and
tender point examination. For the ACR 2010 criteria, data
were derived from the clinic questionnaire and clinical history/
examination. For the ACR modified 2010 criteria, data were
derived from the postal questionnaire.
The prevalence of fibromyalgia was then calculated,
weighting the results to the target population by the inverse of
the sampling fraction, with respect to age, sex, and area of
residence (urban or rural).
Ethics approval. The study was approved by the North
of Scotland Research Ethics Committee (REC reference no.
12/NS/0079).
RESULTS
Of 4,600 questionnaires distributed, 183 were
considered not to have been received by the invited
participant (for example, due to the letter being re-
turned marked as deceased or as no longer resident at
the given address), and 1,604 (36.3%) of the remaining
4,417 eligible invitees returned a completed question-
naire. The median age of the respondents was 55 years
(interquartile range [IQR] 44–65 years), 55% were
female, and the median time from sending the question-
naire to receiving a response was 6 days (IQR 3–16
days).
Of the questionnaire respondents, 269 were in-
vited to attend the research clinic for a clinical exami-
nation; 104 of them (39%) attended, and 32 of those
(31%) were found to meet at least 1 set of criteria for
fibromyalgia: 11 participants met the ACR 1990 criteria,
7 met the ACR 2010 criteria, and 27 met the ACR
modified 2010 criteria. The overlap between different
sets of classification criteria was modest (Figure 1). In
total, only 4 participants (12.5%) met all 3 criteria sets,
and only 9 (28%) met 1 set.
The prevalence of fibromyalgia, as ascertained by
the ACR 1990, 2010, and modified 2010 criteria, which
was weighted back to the characteristics of the target
population, was 1.7% (95% CI 0.7–2.8), 1.2% (95% CI
0.3–2.1), and 5.4% (95% CI 4.7–6.1), respectively. Com-
pared to the ACR 1990 criteria, which was used as the
gold standard, the ACR 2010 criteria had a sensitivity of
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55% and a specificity of 99%; in contrast, these values
for the modified 2010 criteria were 64% and 78%,
respectively.
Patients meeting the ACR 1990 criteria were
predominantly female, with a female-to-male ratio of
13.7:1. The ratio was lower in those meeting the ACR
2010 criteria (4.8:1), and lower still among those meeting
the ACR modified 2010 criteria (2.3:1) (Table 4). There
were also differences in the proportion of participants
who reported prior rheumatologic diagnoses on their
questionnaires (Table 4). This varied from more than
half of those meeting the ACR 1990 criteria, to just over
one-quarter of those meeting the ACR 2010 criteria. It
should be noted, however, that these figures represent
patient-reported diagnoses, which are completely inde-
pendent of whether the examiner thought that the
patient had “a disorder that would otherwise explain the
pain.”
This element of the ACR 2010 criteria (i.e., the
exclusion of patients considered to have an underlying
disorder, which is responsible for their pain) may explain
both the low prevalence (1.2%), and the comparatively
low proportion of cases reporting prior diagnoses. How-
ever, even without this exclusion, the prevalence was still
considerably lower (2.6%) than that ascertained using
the ACR modified 2010 criteria.
All participants who fulfilled both the ACR 2010
and modified 2010 criteria met the latter criteria set by
reporting a high score on the Widespread Pain Index,
rather than the Symptom Severity Scale (Table 5). In
contrast, among the group who met only self-reported
criteria, approximately one-third satisfied the case defi-
nition as a result of high levels of symptoms plus only
moderate levels of pain (Table 5).
DISCUSSION
We have demonstrated that the prevalence of
fibromyalgia varies more than 4-fold with the application
of different ACR fibromyalgia classification criteria sets,
the lowest estimate being with the 2010 criteria and the
highest with the modified 2010 criteria. Further, we have
shown that there are fundamental differences in the
populations identified, in terms of sex ratio and preex-
isting comorbid rheumatologic conditions.
There are a number of methodologic issues to
consider in the interpretation of these findings. First, the
response rate in the initial survey was modest (36%).
Questionnaire survey response rates have been falling
over time (11), and a response of 30–40% is not
uncommon. Compared to those who did not respond,
Figure 1. Overlap among the 3 different case definitions of fibromy-
algia: the American College of Rheumatology (ACR) 1990 criteria, the
ACR 2010 criteria, and the ACR modified 2010 criteria. Of the
respondents to a mailed questionnaire who subsequently attended the
research clinic and underwent examination, 11 met the 1990 criteria, 7
met the 2010 criteria, and 27 met the modified 2010 criteria. Only 4
participants met all 3 criteria sets, and only 9 met more than 1 set.
Table 4. Prevalence of fibromyalgia, according to the ACR criteria
set used
ACR criteria
set
Prevalence
(95% CI)
Female-to-male
ratio
% with
rheumatologic
diagnoses†
1990 criteria 1.7 (0.7–2.8) 13.7 55
2010 criteria 1.2 (0.3–2.1) 4.8 28
Modified
2010 criteria
5.4 (4.7–6.1) 2.3 45
* ACR  American College of Rheumatology; 95% CI  95%
confidence interval.
† Proportion of respondents who had a positive response to the
question “Have you ever been told by a healthcare provider that you
have any of the following diseases: osteoarthritis, rheumatoid arthritis,
osteoporosis, lupus, scleroderma, ankylosing spondylitis, gout, or fi-
bromyalgia?”
Table 5. Proportion of participants who met each case definition in
the ACR modified 2010 criteria, stratified according to the ACR
(non-modified) 2010 criteria
ACR modified 2010 criteria
case definition
ACR 2010 criteria
No. (%)
positive
(n  4)
No. (%)
negative
(n  23)
Widespread Pain Index 7 plus
Symptom Severity Scale score 5
4 (100) 16 (70)
Widespread Pain Index 3–6 plus
Symptom Severity Scale score 9
0 7 (30)
* ACR  American College of Rheumatology.
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questionnaire respondents in the current study were
significantly more likely to be female and were older.
Also, only 39% of the 269 participants invited to attend
the research clinic actually did so. Attenders were more
likely to be male, older, and more likely to live in urban
areas than those who were invited but did not attend.
However, because the initial sampling frame was from
the NHS register, information about age and sex was
available not only on the questionnaire respondents, but
also on all persons invited to participate in the initial
survey. Thus, to counteract the effects of potential
selection (nonparticipation) bias, the prevalence esti-
mates were weighted back to the age and sex distribution
of the target population and on the proportion living in
urban/rural areas.
One limitation of the current study is that gener-
alizations are made about the prevalence of fibromyalgia
based, in some groups, on very small samples. For
example, for men 50 years of age, there were no cases
of fibromyalgia identified using either the ACR 1990
or the ACR 2010 criteria. Accordingly, the weighting
process will assume that there are no cases at all in
this particular population stratum. While this is prob-
ably unlikely, it is known that this is a group that has a
particularly low risk of fibromyalgia (4), and so this
finding is not unexpected.
Another limitation of the current study was the
use of a single clinician (a consultant rheumatologist) for
the clinical examination and case history. The clinical
consultation is inherently a subjective experience, and
it is possible that a different examiner might have come
to a different conclusion regarding the tender points
(ACR 1990 criteria) and/or “a disorder that would
otherwise explain the pain” (ACR 2010 criteria). How-
ever, the use of a single clinician not only more closely
resembles routine clinical practice, but in the context of
a research study, it also has the desirable effect of
reducing any between-participant variation. Further, the
prevalence of fibromyalgia in the current study (1.7%,
as ascertained using the ACR 1990 criteria) is exactly in
the range one might expect based on other earlier
studies in Europe and North America (2–5). Our sample
size precludes a robust examination of differences in
prevalence by various demographic characteristics, but it
is worthy of note that cases, as would be expected, were
more likely to be older females than younger males.
The specificity of the ACR 2010 criteria, as
compared to the ACR 1990 criteria as a gold standard,
was near-perfect. Of the 93 participants identified as not
having fibromyalgia according to the 1990 criteria, 92
were correctly identified by the 2010 criteria. However,
the sensitivity of the 2010 criteria was modest; just over
half of the 1990 fibromyalgia cases were correctly iden-
tified by those criteria. The modified 2010 criteria, while
exhibiting improved sensitivity (more participants posi-
tive for fibromyalgia according to the 1990 criteria were
correctly identified), suffered from a decrease in speci-
ficity (fewer participants negative for fibromyalgia ac-
cording to the 1990 criteria were correctly identified).
Other investigators have examined the sensitivity
and specificity of the modified 2010 criteria in clinical
populations. Bennett et al (12) found a specificity of
67% in patients with non-fibromyalgia chronic pain (i.e.,
33% of people with other chronic pain conditions were
incorrectly classified as having fibromyalgia with the new
criteria). Similar to the current study (specificity of
78%), this is perhaps not surprising and is probably a
function of the willingness of participants to self-report
symptoms that, on physical examination by a clinician,
were not considered eligible for inclusion. This is re-
flected in the fact that none of the participants who met
both the 2010 (clinician-determined) and the modified
2010 (self-report) criteria sets did so as a result of a high
symptoms score: all had a Widespread Pain Index of 7
and a Symptom Severity Scale score of 5, whereas
nearly one-third of the participants who met the self-
report criteria alone had a Widespread Pain Index of
3–6 plus a Symptom Severity Scale score of 9. How-
ever, the numbers in the former group were very small,
and further validation of these findings in another study
is warranted.
The other clear difference between the ACR
2010 and the modified 2010 criteria, other than being
physician-completed versus patient-completed, is the
fourth part of the Symptom Severity Scale. In the
former, the physician is asked to rate somatic symptoms
in general from 0 (no symptoms) to 3 (a great deal of
symptoms), and more than 40 symptoms are listed that
might be considered. Whereas, in the modified 2010
criteria, the same score, 0–3, is based on the patient’s
report of the total number of the following 3 symptoms
that were present during the previous 6 months: head-
aches, pain or cramps in the lower abdomen, and
depression. Agreement between the 2 methods was very
poor (  0.09). Participants were much more likely to
report symptoms (27% reported none; 18% reported all
3) than was reflected in the physician’s assessment of
somatic symptoms generally (66% scored 0; 5% scored
3). This suggests that the former is not a good proxy for
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the latter and explains (at least in part) the increased
prevalence observed with the modified 2010 criteria.
Although the modified 2010 criteria have been
used in several studies (9,13–16), this was almost exclu-
sively in clinical populations, and we believe that the
current study is the first to attempt to implement the
new criteria by a group that is completely independent of
the original author group. We found considerable diffi-
culty operationalizing ACR 2010 criteria for fibromyal-
gia. To satisfy these criteria, a patient must meet several
conditions: first, a certain pattern of pain and somatic
symptoms must be present, and second, it is a require-
ment that “symptoms have been present at a similar
level for at least 3 months.” However, it is not clear from
the proposed 2010 criteria (Table 2) whether this relates
solely to the symptoms encompassed by the Symptom
Severity Scale or whether it also includes pain. In
addition, it is a requirement that the “patient does not
have a disorder that would otherwise explain the pain,”
but similarly, it is not clear whether this relates solely to
the Widespread Pain Index or whether it also includes
some of the (painful) somatic symptoms.
These are subtle but crucial points, and it is likely
that different observers might come to different conclu-
sions about these criteria, even in the same patient. In
the current study, we adopted an inclusive approach and
interpreted “symptoms” to mean “symptoms and/or
pain” and interpreted “pain” to mean “pain and/or other
symptoms.” Therefore, if any bias has been introduced,
it will have served to overestimate the number of
participants with symptoms (or pain) present at a similar
level for at least 3 months, to overestimate the number
of participants with a disorder that would otherwise
explain the pain (or symptoms), and thus, to underesti-
mate the prevalence of fibromyalgia according to the
ACR 2010 criteria.
There was also difficulty operationalizing the
modified 2010 criteria (Table 3). First, they suffer from
the same interpretational problems as the ACR 2010
criteria, as described above. But more importantly, most
patients are not sufficiently qualified to determine
whether they have a disorder that would otherwise
explain the pain (and/or symptoms). In the current
study, although we asked participants to report whether
they had ever been diagnosed as having 1 or more of a
number of rheumatologic conditions, we excluded this
condition when we determined the prevalence according
to this criteria set. This will have served to overestimate
the prevalence of fibromyalgia when using this defini-
tion. This is a concern because these criteria gave the
highest prevalence estimates. However, were we to apply
this condition (i.e., were we to exclude patients who had
previously been diagnosed as having a rheumatologic
condition), the prevalence drops by 44% (from 5.4% to
3.0%). We should stress, however, that on the question-
naire, participants were simply asked whether or not
they had ever received such a diagnosis, and not whether
they thought it explained their pain. Separately, and
blindly with regard to the questionnaire data, the rheu-
matologist who examined the participants came to her
own decision about the presence/absence of a condition,
rheumatologic or otherwise, that might explain the pain
and symptoms. It was this latter assessment that was
used in the application of the ACR 2010 criteria.
The ACR 2010 and modified 2010 criteria re-
flect a conceptual change in the thinking about
fibromyalgia—or at least in the classification of
fibromyalgia—from predominantly a pain syndrome to a
multisymptom syndrome. This paradigm shift may or
may not be appropriate. There is a certain circularity in
classification criteria being developed by clinicians and
then being validated against “clinically diagnosed” pa-
tients (typically, the patients of the same clinicians).
However, using the 2010 criteria, we have shown that
45% of patients previously classified as having fibromy-
algia would now not be classified as such. This may have
important implications for treatment, disability benefits,
and health insurance.
The modified 2010 criteria also reflect a change
from physician-derived classification criteria that are
recommended for use in the clinic to criteria based on
self-report that can be captured in large-scale epidemi-
ologic surveys. However, the performance of these cri-
teria when compared to the ACR 2010 criteria is not
satisfactory, with a sensitivity of 57% and a specificity of
76%.
The current study is the first to compare all 3 sets
of classification criteria in a general population sample,
and our findings do not support previous claims that the
modified 2010 criteria do not result in inflated preva-
lence estimates (9). Furthermore, we have demonstrated
that the new set of criteria defines a demonstrably
different patient group, as compared to that defined by
the 1990 criteria (which they may replace). For example,
the modified 2010 criteria set not only identifies a
greater proportion of men, but also appears to be more
influenced by somatic symptoms than by pain. Most
importantly, operationalization of any new criteria must
be clear and unambiguous, as well as immediately
implementable. This is not currently the case. Both the
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ACR 2010 criteria and the ACR modified 2010 criteria
are currently considered “preliminary,” and we strongly
recommend that the ACR consider these important
issues in deciding whether to confirm these proposed
criteria for use in future clinical practice and/or re-
search.
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